Terrie Curran - Jan 21, 2025 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role
President and Chief Executive, Director
Signature
/s/ Molly Henderson, Attorney-in-Fact for Terrie Curran
Stock symbol
PHAT
Transactions as of
Jan 21, 2025
Transactions value $
-$125,884
Form type
4
Date filed
1/23/2025, 04:19 PM
Previous filing
Nov 13, 2024
Next filing
Mar 3, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHAT Common Stock Sale -$126K -19.1K -5.03% $6.59 360K Jan 21, 2025 Direct F1, F2, F3
holding PHAT Common Stock 3.84K Jan 21, 2025 By 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.5855 to $6.6503. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Includes 1,840 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2025.